These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

415 related articles for article (PubMed ID: 25381477)

  • 1. Influence of dual antiplatelet therapy on mean platelet volume in patients with coronary artery disease undergoing percutaneous coronary intervention.
    Higaki T; Kurisu S; Watanabe N; Ikenaga H; Shimonaga T; Iwasaki T; Mitsuba N; Ishibashi K; Dohi Y; Fukuda Y; Kihara Y
    Heart Vessels; 2016 Mar; 31(3):269-74. PubMed ID: 25381477
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mean platelet volume and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor.
    Verdoia M; Pergolini P; Rolla R; Nardin M; Barbieri L; Schaffer A; Bellomo G; Marino P; Suryapranata H; De Luca G
    Expert Opin Pharmacother; 2015; 16(12):1739-47. PubMed ID: 26067422
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Platelet reactivity and cardiovascular events after percutaneous coronary intervention in patients with stable coronary artery disease: the Stent Thrombosis In Belgium (STIB) trial.
    Legrand V; Cuisset T; Chenu P; Vrolix M; Martinez C; Dens J; Gach O; Boland J; Claeys MJ; Magne J; Barbato E; Wijns W
    EuroIntervention; 2014 Jun; 10(2):204-11. PubMed ID: 24952058
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Routine assessment of on-clopidogrel platelet reactivity and gene polymorphisms in predicting clinical outcome following drug-eluting stent implantation in patients with stable coronary artery disease.
    Viviani Anselmi C; Briguori C; Roncarati R; Papa L; Visconti G; Focaccio A; De Micco F; Latronico MV; Pagnotta P; Condorelli G
    JACC Cardiovasc Interv; 2013 Nov; 6(11):1166-75. PubMed ID: 24262617
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual antiplatelet therapy in patients with a long coronary artery lesion over 30 mm: Determinants and impact on prognosis.
    Manchuelle A; Delhaye C; Schurtz G; Sudre A; Hurt C; Bonello L; Puymirat E; Bauters C; Lemesle G
    Arch Cardiovasc Dis; 2015 Apr; 108(4):235-43. PubMed ID: 25682548
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjunctive cilostazol versus double-dose clopidogrel after drug-eluting stent implantation: the HOST-ASSURE randomized trial (Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis-Safety & Effectiveness of Drug-Eluting Stents & Anti-platelet Regimen).
    Park KW; Kang SH; Park JJ; Yang HM; Kang HJ; Koo BK; Park BE; Cha KS; Rhew JY; Jeon HK; Shin ES; Oh JH; Jeong MH; Kim S; Hwang KK; Yoon JH; Lee SY; Park TH; Moon KW; Kwon HM; Chae IH; Kim HS
    JACC Cardiovasc Interv; 2013 Sep; 6(9):932-42. PubMed ID: 24050860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prolonged CRP Increase After Percutaneous Coronary Intervention Is Associated with High Thrombin Concentrations and Low Platelet' Response to Clopidogrel in Patients with Stable Angina.
    Mostowik M; Siniarski A; Gołębiowska-Wiatrak R; Nessler J; Gajos G
    Adv Clin Exp Med; 2015; 24(6):979-85. PubMed ID: 26771969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of mean platelet aggregation degree on long-term clinical outcomes among patients undergoing a complex percutaneous coronary intervention.
    Li Q; Li M; Yu X; He J; Gao Y; Zhang X; Wu C; Luo Y; Zhang Y; Ren X
    Coron Artery Dis; 2017 Sep; 28(6):478-485. PubMed ID: 28562382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of antiplatelet efficacy and tolerability of clopidogrel napadisilate with clopidogrel bisulfate in coronary artery disease patients after percutaneous coronary intervention: a prospective, multicenter, randomized, open-label, phase IV, noninferiority trial.
    Park JB; Koo BK; Choi WG; Kim SY; Park J; Kwan J; Park CG; Kim HS
    Clin Ther; 2013 Jan; 35(1):28-37.e4. PubMed ID: 23328268
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Importance of the Mean Platelet Aggregation Degree in Long-term Dual Antiplatelet Therapy Following Drug-Eluting Stent Implantation.
    Li Q; Ren X; Yu X; He J; Gao Y; Zhang X; Wu C; Luo Y; Zhang Y; Chen F
    Cardiovasc Ther; 2016 Jun; 34(3):127-37. PubMed ID: 26826703
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of polyunsaturated omega-3 fatty acids on responsiveness to dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: the OMEGA-PCI (OMEGA-3 fatty acids after pci to modify responsiveness to dual antiplatelet therapy) study.
    Gajos G; Rostoff P; Undas A; Piwowarska W
    J Am Coll Cardiol; 2010 Apr; 55(16):1671-8. PubMed ID: 20394870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Parathyroid Hormone Levels and High-Residual Platelet Reactivity in Patients Receiving Dual Antiplatelet Therapy With Acetylsalicylic Acid and Clopidogrel or Ticagrelor.
    Verdoia M; Pergolini P; Rolla R; Nardin M; Barbieri L; Schaffer A; Bellomo G; Marino P; Suryapranata H; De Luca G;
    Cardiovasc Ther; 2016 Aug; 34(4):209-15. PubMed ID: 27086085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacometabolomics analysis of plasma to phenotype clopidogrel high on treatment platelets reactivity in coronary artery disease patients.
    Amin AM; Sheau Chin L; Teh CH; Mostafa H; Mohamed Noor DA; Abdul Kader MASK; Kah Hay Y; Ibrahim B
    Eur J Pharm Sci; 2018 May; 117():351-361. PubMed ID: 29526765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Personalized antiplatelet therapy guided by a novel detection of platelet aggregation function in stable coronary artery disease patients undergoing percutaneous coronary intervention: a randomized controlled clinical trial.
    Zheng YY; Wu TT; Yang Y; Hou XG; Gao Y; Chen Y; Yang YN; Li XM; Ma X; Ma YT; Xie X
    Eur Heart J Cardiovasc Pharmacother; 2020 Jul; 6(4):211-221. PubMed ID: 31603191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Platelet turnover predicts outcome after coronary intervention.
    Freynhofer MK; Iliev L; Bruno V; Rohla M; Egger F; Weiss TW; Hübl W; Willheim M; Wojta J; Huber K
    Thromb Haemost; 2017 May; 117(5):923-933. PubMed ID: 28229159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Variability of platelet response to clopidogrel is not related to adverse cardiovascular events in patients with stable coronary artery disease undergoing percutaneous coronary intervention.
    Olędzki S; Kornacewicz-Jach Z; Safranow K; Kiedrowicz R; Gawrońska-Szklarz B; Jastrzębska M; Gorący J
    Eur J Clin Pharmacol; 2017 Sep; 73(9):1085-1094. PubMed ID: 28589365
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Duration of dual antiplatelet therapy after implantation of the first-generation and second-generation drug-eluting stents.
    Yu X; Chen F; He J; Gao Y; Wu C; Luo Y; Zhang X; Zhang Y; Ren X; Lv S
    Coron Artery Dis; 2013 May; 24(3):217-23. PubMed ID: 23425771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of smoking on the antiplatelet effect of clopidogrel differs according to clopidogrel dose: Insights from the GRAVITAS trial.
    Reed GW; Cannon CP; Waalen J; Teirstein PS; Tanguay JF; Berger PB; Angiolillo DJ; Price MJ
    Catheter Cardiovasc Interv; 2017 Feb; 89(2):190-198. PubMed ID: 26909669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between insulin receptor substrate-1 polymorphisms and high platelet reactivity with clopidogrel therapy in coronary artery disease patients with type 2 diabetes mellitus.
    Zhang D; Zhang X; Liu D; Liu T; Cai W; Yan C; Han Y
    Cardiovasc Diabetol; 2016 Mar; 15():50. PubMed ID: 27005817
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Platelet distribution width as the prognostic marker in coronary bifurcation treatment.
    Kern A; Gil RJ; Bojko K; Sienkiewicz E; Januszko-Giergielewicz B; Górny J; Bil J
    Eur J Clin Invest; 2017 Jul; 47(7):524-530. PubMed ID: 28555728
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.